Initial management as type 2 diabetes means that by the time a clinical and then genetic diagnosis is made, most patents have been treated with agents such as metformin, and increasingly SGLT2 inhibitors or GLP-1 agonists, outside trial settings. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.